Selected research
Market Structure
Global Efavirenz Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Efavirenz market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Efavirenz is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Efavirenz is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Efavirenz is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Efavirenz is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Efavirenz include Teva, Mylan, Macleods Pharmaceuticals, Hetero, Cipla, Bristol-Myers Squibb and Aurobindo Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Efavirenz market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Efavirenz and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Efavirenz sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Efavirenz market size, projected growth trends, production technologies, key applications, and end-use industries.
Efavirenz Segment by Company
Teva
Mylan
Macleods Pharmaceuticals
Hetero
Cipla
Bristol-Myers Squibb
Aurobindo Pharma
Efavirenz Segment by Type
Two-drug combination
Three-drug combination
Efavirenz Segment by Application
Adults
Children
Efavirenz Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Efavirenz market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Efavirenz and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Efavirenz.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Efavirenz market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Efavirenz manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Efavirenz in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Efavirenz in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Two-drug combination
- Three-drug combination
Applications
- Adults
- Children
Companies covered
- Teva
- Mylan
- Macleods Pharmaceuticals
- Hetero
- Cipla
- Bristol-Myers Squibb
- Aurobindo Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Efavirenz Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Efavirenz Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Efavirenz Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Efavirenz Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Efavirenz Market Dynamics
- 2.1 Efavirenz Industry Trends
- 2.2 Efavirenz Industry Drivers
- 2.3 Efavirenz Industry Opportunities and Challenges
- 2.4 Efavirenz Industry Restraints
3 Efavirenz Market by Manufacturers
- 3.1 Global Efavirenz Revenue by Manufacturers (2021-2026)
- 3.2 Global Efavirenz Sales by Manufacturers (2021-2026)
- 3.3 Global Efavirenz Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Efavirenz Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Efavirenz Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Efavirenz Manufacturers, Product Type & Application
- 3.7 Global Efavirenz Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Efavirenz Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Efavirenz Players Market Share by Revenue in 2025
- 3.8.3 2025 Efavirenz Tier 1, Tier 2, and Tier 3
4 Efavirenz Market by Type
- 4.1 Efavirenz Type Introduction
- 4.1.1 Two-drug combination
- 4.1.2 Three-drug combination
- 4.2 Global Efavirenz Sales by Type
- 4.2.1 Global Efavirenz Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Efavirenz Sales by Type (2021-2032)
- 4.2.3 Global Efavirenz Sales Market Share by Type (2021-2032)
- 4.3 Global Efavirenz Revenue by Type
- 4.3.1 Global Efavirenz Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Efavirenz Revenue by Type (2021-2032)
- 4.3.3 Global Efavirenz Revenue Market Share by Type (2021-2032)
5 Efavirenz Market by Application
- 5.1 Efavirenz Application Introduction
- 5.1.1 Adults
- 5.1.2 Children
- 5.2 Global Efavirenz Sales by Application
- 5.2.1 Global Efavirenz Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Efavirenz Sales by Application (2021-2032)
- 5.2.3 Global Efavirenz Sales Market Share by Application (2021-2032)
- 5.3 Global Efavirenz Revenue by Application
- 5.3.1 Global Efavirenz Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Efavirenz Revenue by Application (2021-2032)
- 5.3.3 Global Efavirenz Revenue Market Share by Application (2021-2032)
6 Global Efavirenz Sales by Region
- 6.1 Global Efavirenz Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Efavirenz Sales by Region (2021-2032)
- 6.2.1 Global Efavirenz Sales by Region (2021-2026)
- 6.2.2 Global Efavirenz Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Efavirenz Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Efavirenz Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Efavirenz Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Efavirenz Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Efavirenz Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Efavirenz Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Efavirenz Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Efavirenz Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Efavirenz Revenue by Region
- 7.1 Global Efavirenz Revenue by Region
- 7.1.1 Global Efavirenz Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Efavirenz Revenue by Region (2021-2026)
- 7.1.3 Global Efavirenz Revenue by Region (2027-2032)
- 7.1.4 Global Efavirenz Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Efavirenz Revenue (2021-2032)
- 7.2.2 North America Efavirenz Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Efavirenz Revenue (2021-2032)
- 7.3.2 Europe Efavirenz Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Efavirenz Revenue (2021-2032)
- 7.4.2 Asia-Pacific Efavirenz Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Efavirenz Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Efavirenz Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Teva
- 8.1.1 Teva Company Information
- 8.1.2 Teva Business Overview
- 8.1.3 Teva Efavirenz Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Teva Efavirenz Product Portfolio
- 8.1.5 Teva Recent Developments
- 8.2 Mylan
- 8.2.1 Mylan Company Information
- 8.2.2 Mylan Business Overview
- 8.2.3 Mylan Efavirenz Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Mylan Efavirenz Product Portfolio
- 8.2.5 Mylan Recent Developments
- 8.3 Macleods Pharmaceuticals
- 8.3.1 Macleods Pharmaceuticals Company Information
- 8.3.2 Macleods Pharmaceuticals Business Overview
- 8.3.3 Macleods Pharmaceuticals Efavirenz Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Macleods Pharmaceuticals Efavirenz Product Portfolio
- 8.3.5 Macleods Pharmaceuticals Recent Developments
- 8.4 Hetero
- 8.4.1 Hetero Company Information
- 8.4.2 Hetero Business Overview
- 8.4.3 Hetero Efavirenz Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Hetero Efavirenz Product Portfolio
- 8.4.5 Hetero Recent Developments
- 8.5 Cipla
- 8.5.1 Cipla Company Information
- 8.5.2 Cipla Business Overview
- 8.5.3 Cipla Efavirenz Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Cipla Efavirenz Product Portfolio
- 8.5.5 Cipla Recent Developments
- 8.6 Bristol-Myers Squibb
- 8.6.1 Bristol-Myers Squibb Company Information
- 8.6.2 Bristol-Myers Squibb Business Overview
- 8.6.3 Bristol-Myers Squibb Efavirenz Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Bristol-Myers Squibb Efavirenz Product Portfolio
- 8.6.5 Bristol-Myers Squibb Recent Developments
- 8.7 Aurobindo Pharma
- 8.7.1 Aurobindo Pharma Company Information
- 8.7.2 Aurobindo Pharma Business Overview
- 8.7.3 Aurobindo Pharma Efavirenz Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Aurobindo Pharma Efavirenz Product Portfolio
- 8.7.5 Aurobindo Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Efavirenz Value Chain Analysis
- 9.1.1 Efavirenz Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Efavirenz Production Mode & Process
- 9.2 Efavirenz Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Efavirenz Distributors
- 9.2.3 Efavirenz Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst